Treatment for metastatic colorectal cancer (mCRC) commonly involves a fluoropyrimidine-based chemotherapy regimen such as infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) or fluorouracil, leucovorin, and oxaliplatin, often combined with bevacizumab or an epidermal growth factor receptor monoclonal antibody. We studied the effect of adding the novel antiangiogenic agent aflibercept (also known as ziv-aflibercept in the United States) to FOLFIRI in patients with mCRC previously treated with oxaliplatin, including patients who received prior bevacizumab.
INTRODUCTION
Colorectal cancer is the second most common cancer in women and the third most common cancer in men, with an estimated worldwide incidence of more than 1.2 million in 2008, and mortality over 600,000.
1 Firstline metastatic colorectal cancer (mCRC) treatment typically involves a fluoropyrimidine-based chemotherapy regimen, combining infusional fluorouracil (FU) and leucovorin with oxaliplatin (FOLFOX regimen) or irinotecan (FOLFIRI regimen), with a cross-over to the alternate regimen for second-line treatment. [2] [3] [4] More recently, the targeted biologic therapy bevacizumab or an epidermal growth factor receptor monoclonal antibody has been added to these combinations. In relation to vascular endothelial growth factor (VEGF) blockade, bevacizumab blocks VEGFA and has been shown to increase survival in the first-line setting when added to irinotecan, bolus fluorouracil and leucovorin 5 or in the second-line setting with the FOLFOX regimen. 6 To date, no biologic therapy has been shown to provide a statistically significant survival benefit in the second-line setting in patients previously treated with an oxaliplatin-based regimen who are being treated with FOLFIRI.
Aflibercept (also known as VEGF Trap, AVE0005, or zivaflibercept in the United States) is a recombinant fusion protein containing VEGF-binding portions from the extracellular domains of human VEGF receptors 1 and 2, fused to the Fc portion of human immunoglobulin (Ig)G1. Aflibercept blocks the activity of VEGFA, VEGFB, and placental growth factor (PlGF) by acting as a high-affinity ligand trap to prevent these ligands from binding to their endogenous receptors. In nonclinical studies, aflibercept has been demonstrated to block tumor growth in vivo with a potent antiangiogenic action. 7, 8 Results from these studies suggest that levels of free aflibercept in excess of bound aflibercept were necessary for optimal pharmacologic activity. Phase I dose-escalation studies and phase II studies have explored the use of aflibercept as a single agent and in combination with a number of chemotherapy agents/regimens, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] including in patients with mCRC treated with irinotecan, FU, and leucovorin. 14, 15 In the latter study, 15 administering aflibercept at a dose of 4 mg/kg every 2 weeks resulted in a mean ratio for free-over-bound aflibercept trough concentrations greater than 1 in most patients and resulted in a high rate of disease control in heavily pretreated patients, together with an acceptable safety profile.
The purpose of this prospective multinational, randomized, double-blind, parallel-arm, phase III study was to evaluate the efficacy and safety of the combination of aflibercept plus FOLFIRI versus placebo plus FOLFIRI in patients with mCRC, following disease progression while on or after completion of treatment with an oxaliplatinbased regimen.
PATIENTS AND METHODS

Patients
Eligible patients were at least 18 years old; with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2. Eligible patients had histologically or cytologically proven colorectal adenocarcinoma with metastatic disease not amenable to potentially curative treatment; measurable disease was not a requirement for participation. Although patients were to have documented progression while on or after completion of a single prior oxaliplatin-containing regimen, they were not selected for the timing of their progression. Patients who experienced relapse within 6 months of completion of oxaliplatin-based adjuvant therapy were eligible. Prior bevacizumab was permitted, but not prior irinotecan. Randomization occurred 28 days or more after cessation of prior radiotherapy or chemotherapy and 30 days or more after ending participation in another clinical trial involving an investigational drug. Patients with a history of major surgery within 28 days were not allowed to participate.
Eligible patients had no known prior malignancies or known brain metastases; however, patients with adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or any other cancer from which the patient had been disease-free for more than 5 years were permitted. No severe acute or chronic medical condition that may have impaired the ability to participate in the study or interfered with the interpretation of results was permitted. Adverse events from prior anticancer therapy were to have recovered to grade Յ 1 (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 3.0) before randomization. Patients were to have had no history of uncontrolled hypertension within 3 months before enrollment and no deep vein thrombosis within 4 weeks before randomization. Patients were to have adequate organ and hematologic function. Pregnant and breast-feeding women were excluded. Patients of reproductive potential were required to use effective methods of contraception.
The study protocol was approved by local institutional review boards and ethics committees in accordance with national and international guidelines; all patients signed a written informed consent document. An independent data monitoring committee reviewed the progress of the trial to ensure patient safety.
Randomization and Treatment
Eligible patients were randomly assigned, 1:1, to receive aflibercept plus FOLFIRI (aflibercept arm) or placebo plus FOLFIRI (control arm) using a centralized interactive voice response system based on a permuted-block randomization, stratified according to prior therapy with bevacizumab (yes or no), and ECOG PS (0, 1, or 2).
Patients received 4 mg/kg of aflibercept or placebo (intravenously [IV] ), according to treatment assignment, over 1 hour on day 1 every 2 weeks, followed immediately by the FOLFIRI regimen (irinotecan 180 mg/m 2 IV over 90 minutes, with leucovorin 400 mg/m 2 IV over 2 hours, followed by FU 400 mg/m 2 bolus and FU 2400 mg/m 2 continuous infusion over 46 hours). Premedication with atropine and antiemetics was permitted. Granulocyte colonystimulating factor was used according to American Society of Clinical Oncology guidelines.
22 Dose adjustments for each study treatment component individually and/or cycle delays (up to 2 weeks) were permitted in the event of toxicity. Patients were to be treated until occurrence of disease progression or unacceptable toxicity according to physician judgment. If FOLFIRI was permanently discontinued, patients could continue to receive aflibercept/ placebo; if aflibercept/placebo was permanently discontinued, patients could continue to receive FOLFIRI. No cross-over to aflibercept was permitted after progression was documented in the control arm.
Assessments
Pretreatment evaluation included medical history (including cancer history, prior anticancer treatments), clinical examination (including ECOG PS, blood pressure, ECG), laboratory analyses (CBC and coagulation tests, blood chemistry, morning urine spot for evaluation of proteinuria), and tumor assessment by appropriate imaging techniques.
At each treatment cycle, patients underwent clinical examination and laboratory assessments (including urinalysis) before receiving study treatment. Adverse events (according to NCI-CTCAE v3.0) and concomitant medications were recorded. Disease assessment was performed every 6 weeks until documented progression. Response was assessed according to RECIST (Response Evaluation Criteria In Solid Tumors, version 1.0) 23 by a third party (independent review committee), blinded to patient treatment.
Patients who discontinued treatment before disease progression were followed every 6 weeks for progression-free survival (PFS). Once progression was documented (according to investigator evaluation), surviving patients were followed every 8 weeks for survival, until death or study cutoff.
Statistical Analysis
The primary end point of this study was overall survival (OS), defined as the time interval from randomization to death from any cause. It was determined that 863 events were required to detect, with 90% power, a 20% risk reduction in the aflibercept arm relative to the control arm, using a log-rank test at an overall two-sided significance level of .0499, taking into account stopping boundaries for two interim analyses. Using a group sequential approach with an O'Brien Fleming ␣-spending function and an overall twosided ␣ level of .0499, the two-sided ␣ nominal significance level to be used at the final analysis of OS was .0466. On the basis of an anticipated accrual over 30 months with 9 months follow-up, a total of 1,200 patients were required. The cutoff date for OS was the date of the 863rd event (February 7, 2011). PFS was a secondary efficacy end point, defined as the interval from randomization to the first observation of disease progression (according to independent review committee review) or death from any cause. Additional secondary end points included objective response (complete response and partial response) and treatment-emergent adverse events and laboratory abnormalities.
Efficacy analyses were conducted in the randomized population according to the arm assigned at randomization; response rate was assessed in the subset of these patients who had measurable disease at baseline. Time-to-event parameters were estimated using Kaplan-Meier analysis. Primary comparisons between treatment groups were performed using stratified log-rank tests with stratification factors specified at randomization. In prespecified subgroup analyses, the consistency of the treatment effect on OS was evaluated with respect to stratification factors at randomization (interactive voice response system: ECOG PS, prior bevacizumab) and a series of baseline characteristics: age, sex, location of primary tumor, number of organs with metastasis, liver metastasis, prior hypertension, and geographical region. The hazard ratio and CI estimates in the primary and subgroup analyses were provided using a Cox proportional hazards model. Response rate was compared between arms using a Cochran-Mantel-Haenszel test.
Safety was analyzed using descriptive methods, in the treated population, according to the treatment received (patients who received at least one dose of aflibercept were analyzed in the aflibercept arm, regardless of treatment assignment).
All final analyses were conducted by Sanofi personnel.
RESULTS
Between November 2007 and March 2010, 1,401 patients were screened in 176 centers in 28 countries, with 1,226 patients randomly assigned to receive, in combination with FOLFIRI, either aflibercept (612 patients) or placebo (614 patients). Five patients in each treatment arm were not treated. Because four patients randomly assigned to placebo received at least one administration of aflibercept, the safety population included 611 patients in the aflibercept arm and 605 in the control arm (Fig 1) .
Patients
Patient characteristics and disease history (including prior anticancer treatments) were well balanced between the two treatment arms (Table 1). Prior bevacizumab treatment was reported in 373 patients overall (30.4%), and 534 patients (43.6%) had prior hypertension.
Patients in the aflibercept arm received 6,362 cycles, compared with 6,127 cycles in the control arm. In the aflibercept arm, patients received a medianofninecyclesoverall(21.4weeks),withamedianofsevencyclesof aflibercept; in contrast, patients in the control arm received a median of eight cycles overall (18.1 week), with a median of eight cycles of placebo. Irinotecan and FU were administered for a median of 21.0 weeks in the aflibercept arm and 18.1 week in the control arm. Median relative doseintensity was 83% for patients in the aflibercept arm versus 92% for patients in the control arm. Cycle delays were reported in 77.7% of patients in the aflibercept arm and 69.4% of patients in the control arm; dose modifications were implemented in more patients in the aflibercept arm than in the control arm (aflibercept/placebo, 16.7% v 4.8%; irinotecan, 37.2% v 22.6%; FU, 39.1% v 21.7%, respectively). Allocated to FOLFIRI/placebo (n = 614) Received allocated intervention (n = 605) Did not receive allocated intervention (n = 9)
Analyzed (in primary analysis) (n = 614) Excluded from analysis (n = 0) ) 5 0 6 = n ( s i s y l a n a y t e f a S Excluded from analysis (n = 5, not treated) Received at least 1 dose of (n = 4) aflibercept; analyzed in aflibercept arm Analyzed (in primary analysis) (n = 612) Excluded from analysis (n = 0) )
Excluded from analysis (n = 5, not treated)
Did not meet inclusion criteria (n = 123) Declined to participate (n = 17) Other reasons (n = 35) Fig 1. CONSORT diagram. Measurable disease was not a study entry criterion, therefore only patients with measurable disease at baseline were assessed for objective response. Response rate was assessed in 530 patients in the placebo group and 531 patients in the aflibercept group and was based on assessment by an independent review committee blinded to random assignment. Independent review was also used for determination of progression in the progression-free survival analysis, except for 42 patients who did not give consent for this review and for whom investigator assessment was therefore used. The cutoff date for primary analysis of overall survival was 07 February 2011; 25 patients were still receiving study treatment at this point. FOLFIRI, irinotecan, leucovorin and fluorouracil; PD, progressive disease.
Efficacy
At the cutoff date for survival analysis, the median follow-up time for the intent-to-treat population was 22.28 months. Analysis was based on 403 events in the aflibercept arm and 460 events in the control arm. Figure 2A shows survival outcomes in the two treatment arms. Patients receiving aflibercept plus FOLFIRI had a statistically significantly longer survival than patients receiving placebo plus FOLFIRI (median survival, 13.50 v 12.06 months, respectively; Table 2), with a hazard ratio of 0.817 (95.34% CI, 0.713 to 0.937; P ϭ .0032). Two-year survival rates were 28.0% in the aflibercept arm and 18.7% in the control arm (Table 2) . Prespecified subgroup analyses based on stratification factors (prior bevacizumab status and ECOG PS) indicated a treatment effect for each subgroup that exhibited a consistent trend, with aflibercept improving OS without significant interaction effects (Fig 3A) . Further prespecified subgroup analyses of OS based on baseline characteristics, including age, sex, location of primary tumor, number of organs with metastasis, liver metastasis, prior hypertension, and geographical region, also showed a consistent benefit associated with the addition of aflibercept to FOLFIRI across almost all subgroups (data not shown). Addition of aflibercept to FOLFIRI also increased PFS relative to placebo plus FOLFIRI (hazard ratio, 0.758; 95% CI, 0.661 to 0.869; P Ͻ .0001; Fig 2B) . Median PFS, based on independent assessment of radiologic progression, was 6.9 months in the aflibercept arm and 4.7 months in the control arm. Subgroup analyses, using the same subgroups as for the survival analysis, exhibited a consistent trend in PFS advantage for the aflibercept arm over the control arm (Fig 3B) .
Response rate was 19.8% in the aflibercept arm and 11.1% in the control arm (P Ͻ .001, Table 2 ). Overall, 165 patients were excluded from response rate analysis (aflibercept arm 13.2%, control arm 13.7%), primarily due to nonmeasurable disease at baseline.
Safety
Treatment-emergent adverse events were reported in 99.2% and 97.9% of the aflibercept arm and control arm patients, respectively, Abbreviation: FOLFIRI, infusional fluorouracil, leucovorin, and irinotecan.
‫ء‬
with grade 3 and 4 events reported in 83.5% and 62.5% of patients, respectively. Table 3 summarizes the incidence at all grades and at grades 3 and 4 of the most frequently reported adverse events, including also the incidence of events that may be typically associated with anti-VEGF therapy. In particular, a higher incidence of grade 3 and 4 adverse events was reported in the aflibercept arm compared with the control arm for hypertension, hemorrhage (2.9% v 1.7%), arterial thromboembolic events (1.8% v 0.5%), and venous thromboembolic events (7.9% v 6.3%). With respect to the grade 3 and 4 hypertension, 19.1% of patients in the aflibercept arm and 1.5% of patients in the control arm developed grade 3 hypertension (ie, requiring adjustment in existing antihypertensive therapy or treatment with more than one drug); only one patient in the aflibercept arm (0.2%) experienced grade 4 hypertension. The incidence of grade 3 or 4 GI fistula, other fistulae, and GI perforation was less than 2% in both treatment groups; acute grade 3 and 4 drug reactions were reported in 0.5% of patients in both arms. Grade 3 or 4 proteinuria was reported in 7.9% of patients in the aflibercept arm (including two patients with nephrotic syndrome) and 1.2% of patients in the control arm. Some adverse events commonly associated with chemotherapy were reported at a higher incidence in the aflibercept arm, including the following grade 3 and 4 events: diarrhea (19.3% v 7.8%), asthenic conditions (16.9% v 10.6%), stomatitis and ulceration (13.7% v 5.0%), infections (12.3% v 6.9%), and palmar-plantar erythrodysesthesia (2.8% v 0.5%). Grade 3 and 4 neutropenia (36.7% v 29.5%) and thrombocytopenia (3.3% v 1.7%) were more common with aflibercept treatment, as was grade 3 and 4 complicated neutropenia (5.7% v 2.8%).
Adverse events led to permanent discontinuation from study treatment in 26.8% of patients in the aflibercept arm and 12.1% of patients in the control arm. The adverse events (all grades) leading most frequently to permanent discontinuation of study treatment were asthenic conditions (3.8% v 1.3%, respectively), infections (3.4% v 1.7%), diarrhea (2.3% v 0.7%), and hypertension (2.3% v 0%).
DISCUSSION
This phase III study examined the effects of adding aflibercept to FOLFIRI in patients with mCRC who had progressed on or after previous treatment with an oxaliplatin-based chemotherapy regimen. The choice to use a control arm of FOLFIRI with placebo rather than using an active comparator added to FOLFIRI was appropriate because at the time of study design, there were no data available demonstrating a survival benefit with FOLFIRI combined with a targeted antiangiogenic therapy in patients previously treated for metastatic disease. Aflibercept combined with FOLFIRI statistically significantly improved OS when compared with placebo plus FOLFIRI (hazard ratio, 0.817; P ϭ .0032). The clinical value of these results, which represent a relative reduction in the risk of death of 18.3% in the aflibercept plus FOLFIRI arm, is further supported by the early and continued divergence of the survival curves, with persistence of the survival effect beyond the median survival time. does not fully reflect the overall clinical benefit of adding aflibercept to FOLFIRI as opposed to landmark estimates assessed after 18, 24, and 30 months.
Furthermore, the observed effect of the aflibercept/FOLFIRI combination on efficacy is robust and seen across all study efficacy end points (OS, PFS, and response). This effect did not seem to be confounded by differences in anticancer treatment administered to patients after study treatment ended (Table 2 ). The efficacy effect remained consistent across multiple subgroups, as well as in planned sensitivity analyses (data not shown). Interestingly, as shown in Figure  3 , there is no evidence of heterogeneity of treatment effect with regard to prior exposure to bevacizumab on both PFS and OS results, as indicated by P values of more than .1, indicating there is no evidence of interaction between treatment and subgroups when tested at the twosided 10% level. These observations may be indicative of a broad antiangiogenic effect of aflibercept, with its mechanism of action in targeting VEGFA, VEGFB, and PlGF, factors that contribute to tumor angiogenesis.
24-26
The activity of this combination resulted in a clinical benefit accompanied by an expected increase in adverse effects, both those attributable to the chemotherapy backbone and to the anti-VEGF agent. Some of the common adverse effects associated with FOLFIRI, such as diarrhea, stomatitis, infection, neutropenia, and neutropenic complications, were enhanced when FOLFIRI was administered in combination with aflibercept. Anti-VEGF treatment-related toxicities (eg, hypertension, mucosal bleeding, and proteinuria) were also reported in more patients in the aflibercept arm than in the control arm. GI perforation, hemorrhage, and arterial thromboembolism were infrequent in the study, although hemorrhage and arterial thromboembolism were reported more frequently in the aflibercept arm. Previous studies with aflibercept are consistent with this safety profile.
27 Importantly, there were no new toxicity signals.
In summary, the combination of aflibercept with FOLFIRI provides a statistically significant improvement in OS and in the other efficacy end points analyzed in patients with mCRC previously treated with an oxaliplatin-based regimen. Aflibercept, which prevents VEGFA, VEGFB, and PlGF from binding to their receptors, is the first agent to demonstrate a survival benefit in patients previously treated with an oxaliplatin-based regimen who are being treated with FOLFIRI for their metastatic disease. Aflibercept plus FOLFIRI may provide a new therapeutic option for the treatment of mCRC in patients previously treated with oxaliplatin.
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